



GEM

Seitz-Polski B, Debiec H, Rousseau A, Dahan K, Zaghrini C, Payré C, Esnault V, Lambeau G, Ronco P. Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy. J Am Soc Nephrol, 2017, sous presse, doi: <https://doi.org/10.1681/ASN.2017070734>

1. Philipponnet C, Ronco P, Aniort J, Kemeny JL, Heng AE. Membranous Nephropathy and Intrarenal Extramedullary Hematopoiesis in a Patient With Myelofibrosis. Am J Kidney Dis. 2017 Aug 16. pii: S0272-6386(17)30834-X. doi: 10.1053/j.ajkd.2017.06.022.
2. Pourcine F, Dahan K, Mihout F, Cachanado M, Brocheriou I, Debiec H, Ronco P. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years. PLoS One. 2017 Mar 3;12(3):e0173201. doi: 10.1371/journal.pone.0173201.
3. Cui Z, Xie LJ, Chen FJ, Pei ZY, Zhang LJ, Qu Z, Huang J, Gu QH, Zhang YM, Wang X, Wang F, Meng LQ, Liu G, Zhou XJ, Zhu L, Lv JC, Liu F, Zhang H, Liao YH, Lai LH, Ronco P, Zhao MH. MHC Class II Risk Alleles and Amino Acid Residues in Idiopathic Membranous Nephropathy. J Am Soc Nephrol. 2017 May;28(5):1651-1664. doi: 10.1681/ASN.2016020114.
4. Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, Michel PA, Mihout F, Dussol B, Matignon M, Mousson C, Simon T, Ronco P; GEMRITUX Study Group. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. J Am Soc Nephrol. 2017 Jan;28(1):348-358. doi: 10.1681/ASN.2016040449.
5. Bally S, Debiec H, Ponard D, Dijoud F, Rendu J, Fauré J, Ronco P, Dumestre-Perard C. Phospholipase A2 Receptor-Related Membranous Nephropathy and Mannan-Binding Lectin Deficiency. J Am Soc Nephrol. 2016 Dec;27(12):3539-3544.
6. Ronco P, Debiec H. Membranous nephropathy: A fairy tale for immunopathologists, nephrologists and patients. Mol Immunol. 2015 Nov;68(1):57-62. doi: 10.1016/j.molimm.2015.07.003.
7. Pozdzik AA, Debiec H, I Brochériou, Husson C, Rorive S, Broeders N, Le Moine A, Ronco P, Nortier J. [Anti-NEP and anti-PLA2R antibodies in membranous nephropathy: an update]. Rev Med Brux. 2015 May-Jun;36(3):166-71.
8. Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. Lancet. 2015 May 16;385(9981):1983-92. doi: 10.1016/S0140-6736(15)60731-0.
9. Stehlé T, Audard V, Ronco P, Debiec H. Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy. Nephrol Dial Transplant. 2015 Jun;30(6):1047-50. doi: 10.1093/ndt/gfv080.

10. Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pellé T, Gaspari F, Suardi F, Gagliardini E, Orisio S, Benigni A, Ronco P, Remuzzi G. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. *J Am Soc Nephrol*. 2015 Oct;26(10):2545-58. doi: 10.1681/ASN.2014070640.
11. Vivarelli M, Emma F, Pellé T, Gerken C, Pedicelli S, Diomedi-Camassei F, Klaus G, Waldegger S, Ronco P, Debiec H. Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies. *Kidney Int*. 2015 Mar;87(3):602-9. doi: 10.1038/ki.2014.381
12. Ronco P, Debiec H. Anti-phospholipase A2 receptor antibodies and the pathogenesis of membranous nephropathy. *Nephron Clin Pract*. 2014;128(3-4):232-7. doi: 10.1159/000368588. Epub 2014 Nov 11.
13. Meyrier A, Ronco P. Allotransplantation using a diseased kidney: when a swallow makes a summer. *Nephrol Dial Transplant*. 2014 Dec;29(12):2164-6. doi: 10.1093/ndt/gfu336.
14. Debiec H, Ronco P. Immunopathogenesis of membranous nephropathy: an update. *Semin Immunopathol*. 2014 Jul;36(4):381-97. doi: 10.1007/s00281-014-0423-y. Epub 2014 Apr 9.
15. Ronco P, Debiec H. [Anti-CD 10 maternal-fetal allo-immunisation]. *Bull Acad Natl Med*. 2012 Nov;196(8):1613-22; discussion 1622-3.
16. Debiec H, Valayannopoulos V, Boyer O, Noël LH, Callard P, Sarda H, de Lonlay P, Niaudet P, Ronco P. Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: a need for tolerance induction therapy. *J Am Soc Nephrol*. 2014 Apr;25(4):675-80. doi: 10.1681/ASN.2013030290.
17. Taton B, Moreau K, Lepreux S, Bachelet T, Trimoulet P, De Ledinghen V, Pommereau A, Ronco P, Kamar N, Merville P, Couzi L. Hepatitis E virus infection as a new probable cause of de novo membranous nephropathy after kidney transplantation. *Transpl Infect Dis*. 2013 Dec;15(6):E211-5. doi: 10.1111/tid.12143.
18. Weening JJ, Ronco P, Remuzzi G. Advances in the pathology of glomerular diseases. *Contrib Nephrol*. 2013;181:12-21. doi: 10.1159/000348639.
19. Ronco P, Debiec H, Imai H. Circulating antipodocyte antibodies in membranous nephropathy: pathophysiologic and clinical relevance. *Am J Kidney Dis*. 2013 Jul;62(1):16-9. doi: 10.1053/j.ajkd.2013.03.016.
20. Coenen MJ, Hofstra JM, Debiec H, Stanescu HC, Medlar AJ, Stengel B, Boland-Augé A, Groothuismink JM, Bockenhauer D, Powis SH, Mathieson PW, Brenchley PE, Kleta R, Wetzels JF, Ronco P. Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy. *J Am Soc Nephrol*. 2013 Mar;24(4):677-83. doi: 10.1681/ASN.2012070730.
21. Sendeyo K, Audard V, Zhang SY, Fan Q, Bouachi K, Ollero M, Rucker-Martin C, Gouadon E, Desvaux D, Bridoux F, Guellaën G, Ronco P, Lang P, Pawlak A, Sahali D. Upregulation of c-mip is closely related to podocyte dysfunction in membranous nephropathy. *Kidney Int*. 2013 Mar;83(3):414-25. doi: 10.1038/ki.2012.426.

22. Ronco P, Debiec H. [Pathophysiology of extramembranous glomerulopathies. Fifty years of progress, from laboratory to patient]. *Biol Aujourdhui*. 2013;207(4):249-59. doi: 10.1051/jbio/2013025.
23. Svobodova B, Honsova E, Ronco P, Tesar V, Debiec H. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. *Nephrol Dial Transplant*. 2013 Jul;28(7):1839-44. doi: 10.1093/ndt/gfs439.
24. Debiec H, Hanoy M, Francois A, Guerrot D, Ferlicot S, Johanet C, Aucouturier P, Godin M, Ronco P. Recurrent membranous nephropathy in an allograft caused by IgG3k targeting the PLA2 receptor. *J Am Soc Nephrol*. 2012 Dec;23(12):1949-54. doi: 10.1681/ASN.2012060577.
25. Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. *J Am Soc Nephrol*. 2012 Oct;23(10):1735-43.
26. Cambier JF, Ronco P. Onco-nephrology: glomerular diseases with cancer. *Clin J Am Soc Nephrol*. 2012 Oct;7(10):1701-12. doi: 10.2215/CJN.03770412.
27. Zaidan M, Ebbo M, Brochériou I, Ronco P, Schleinitz N, Boffa JJ. [IgG4-related disease and renal and urological involvement]. *Nephrol Ther*. 2012 Dec;8(7):499-507. doi: 10.1016/j.nephro.2012.02.007.
28. Ronco P, Debiec H. Pathogenesis of membranous nephropathy: recent advances and future challenges. *Nat Rev Nephrol*. 2012 Feb 28;8(4):203-13. doi: 10.1038/nrneph.2012.35.
29. Ronco P, Debiec H. [Idiopathic and secondary membranous nephropathies]. *Presse Med*. 2012 Mar;41(3 Pt 1):290-7. doi: 10.1016/j.lpm.2011.11.004.

FSGS

1. Lescure FX, Fleteau C, Pacanowski J, Brocheriou I, Rondeau E, Girard PM, Ronco P, Pialoux G, Plaisier E. HIV-associated kidney glomerular diseases: changes with time and HAART. *Nephrol Dial Transplant*. 2012 Jun;27(6):2349-55. doi: 10.1093/ndt/gfr676.

Minimal Change Disease

1. Okpechi IG, Ameh OI, Bello AK, Ronco P, Swanepoel CR, Kengne AP. Epidemiology of Histologically Proven Glomerulonephritis in Africa: A Systematic Review and Meta-Analysis. *PLoS One*. 2016 Mar 24;11(3):e0152203. doi: 10.1371/journal.pone.0152203.
2. Kimura Y, Miura N, Debiec H, Morita H, Yamada H, Banno S, Ronco P, Imai H. Circulating antibodies to α -enolase and phospholipase A(2) receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy. *Clin Exp Nephrol*. 2017 Feb;21(1):117-126. doi: 10.1007/s10157-016-1235-2.
3. Kofman T, Zhang SY, Copie-Bergman C, Moktefi A, Raimbourg Q, Francois H, Karras A, Plaisier E, Painchart B, Favre G, Bertrand D, Gyan E, Soud M, Roos-Weil D, Desvaux D, Grimbert P, Haioun C, Lang

- P, Sahali D, Audard V. Minimal change nephrotic syndrome associated with non-Hodgkin lymphoid disorders: a retrospective study of 18 cases. *Medicine (Baltimore)*. 2014 Nov;93(24):350-8. doi: 10.1097/MD.0000000000000206.
4. Smeets B, Stucker F, Wetzels J, Brocheriou I, Ronco P, Gröne HJ, D'Agati V, Fogo AB, van Kuppevelt TH, Fischer HP, Boor P, Floege J, Ostendorf T, Moeller MJ. Detection of activated parietal epithelial cells on the glomerular tuft distinguishes early focal segmental glomerulosclerosis from minimal change disease. *Am J Pathol*. 2014 Dec;184(12):3239-48. doi: 10.1016/j.ajpath.2014.08.007.
 5. Muniyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R, Deschênes G, Ronco PM, Plaisier EM, Dahan KY. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. *Kidney Int*. 2013 Mar;83(3):511-6. doi: 10.1038/ki.2012.444.